Patents Assigned to Genentech
  • Treatment of cancer using anti-Apo-2 antibodies
    Patent number: 7595046
    Abstract: Novel polypeptides, designated Apo-2, which are capable of modulating apoptosis are provided. Compositions including Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 are also provided.
    Type: Grant
    Filed: December 9, 2005
    Date of Patent: September 29, 2009
    Assignee: Genentech, Inc.
    Inventors: Camellia W. Adams, Avi J. Ashkenazi, Anan Chuntharapai, Kyung Jin Kim
  • Tyrosine derivatives
    Patent number: 7595399
    Abstract: The compounds of the invention are inhibitors of alpha4 containing integrin-mediated binding to ligands such as VCAM-1 and MAdCAM.
    Type: Grant
    Filed: February 4, 2004
    Date of Patent: September 29, 2009
    Assignee: Genentech, Inc.
    Inventors: David Y. Jackson, Frederick C. Sailes, Daniel P. Sutherlin
  • GENE DETECTION ASSAY FOR IMPROVING THE LIKELIHOOD OF AN EFFECTIVE RESPONSE TO AN EGFR ANTAGONIST CANCER THERAPY
    Publication number: 20090239236
    Abstract: The invention provides a method for more effective treatment of patients susceptible to or diagnosed with tumors overexpressing EGFR, as determined by a gene amplification assay, with an EGFR antagonist. Such method comprises administering a cancer-treating dose of the EGFR antagonist, preferably in addition to chemotherapeutic agents, to a subject in whose tumor cells erbB1 gene has been found to be amplified e.g., by fluorescent in situ hybridization. EGFR antagonists described include an anti-EGFR antibody.
    Type: Application
    Filed: May 26, 2009
    Publication date: September 24, 2009
    Applicant: Genentech, Inc.
    Inventor: Robert D. Mass
  • Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
    Patent number: 7592439
    Abstract: A method of making monoclonal antibodies according to a mixed antigen immunization protocol is described. In addition, antibodies obtainable by the method are disclosed which specifically cross-react with two or more different receptors to which Apo-2 ligand (Apo-2L) can bind.
    Type: Grant
    Filed: April 24, 2007
    Date of Patent: September 22, 2009
    Assignee: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Anan Chuntharapai, K. Jin Kim
  • PRO256 polypeptides
    Patent number: 7589172
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: September 6, 2002
    Date of Patent: September 15, 2009
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Austin L. Gurney, Paul J. Godowski, William I. Wood, Victoria Smith
  • COMBINATION THERAPY WITH C-MET AND HER ANTAGONISTS
    Publication number: 20090226455
    Abstract: The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention relates to combination therapies for the treatment of pathological conditions, such as cancer.
    Type: Application
    Filed: March 6, 2009
    Publication date: September 10, 2009
    Applicant: Genentech, Inc.
    Inventor: Ellen Filvaroff
  • COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS
    Publication number: 20090226443
    Abstract: The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention relates to combination therapies for the treatment of pathological conditions, such as cancer.
    Type: Application
    Filed: March 6, 2009
    Publication date: September 10, 2009
    Applicant: Genentech, Inc.
    Inventors: Ellen Filvaroff, Mark Merchant, Robert L. Yauch
  • SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME
    Publication number: 20090226953
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Application
    Filed: November 13, 2008
    Publication date: September 10, 2009
    Applicant: Genentech, Inc.
    Inventors: Kevin P. Baker, Luc Desnoyers, Mary E. Gerritsen, Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, Victoria Smith, Jean-Philippe F. Stephan, Colin K. Watanabe, William I. Wood
  • METHOD FOR TREATING DEMENTIA OR ALZHEIMER'S DISEASE
    Publication number: 20090226439
    Abstract: Methods for treating Alzheimer's disease (AD) or dementia using a CD20 antibody are described. Articles of manufacture for use in such methods are also described.
    Type: Application
    Filed: April 17, 2009
    Publication date: September 10, 2009
    Applicant: Genentech, Inc.
    Inventor: Martin E. Sanders
  • ?-heregulin
    Patent number: 7585673
    Abstract: A novel member of the heregulin superfamily has been identified which is designated “?-HRG”. This molecule, secreted by human breast cancer MDA-MB-175 cells, leads to the formation of a constitutive active receptor complex and stimulates the growth of these cells in an autocrine manner. ?-HRG polypeptide and nucleic acid are disclosed, together with various uses therefor (e.g. use of ?-HRG nucleic acid for the recombinant production of ?-HRG). ?-HRG antagonists (e.g. neutralizing antibodies and antisense nucleic acid molecules) as well as uses therefor are also described.
    Type: Grant
    Filed: July 1, 2005
    Date of Patent: September 8, 2009
    Assignee: Genentech, Inc.
    Inventors: Gabriele Maria Schaefer, Mark Sliwkowski
  • Antibodies specific for TAT285-1
    Patent number: 7585953
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: September 13, 2005
    Date of Patent: September 8, 2009
    Assignee: Genentech, Inc.
    Inventors: Ruihuan Chen, Heidi S. Phillips, P. Mickey Williams, Thomas Wu, Zemin Zhang
  • Anti-PRO6308 antibodies
    Patent number: 7582293
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods, for producing the polypeptides of the present invention.
    Type: Grant
    Filed: September 12, 2002
    Date of Patent: September 1, 2009
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Austin L. Gurney, Paul J. Godowski, William I. Wood, Mary Gerritsen
  • Anti-interferon-? antibodies
    Patent number: 7582445
    Abstract: Compositions of matter encoding or useful for expressing anti-interferon alpha antibodies are provided. Methods of using such compositions of matter for producing anti-interferon alpha antibodies are also provided.
    Type: Grant
    Filed: March 10, 2006
    Date of Patent: September 1, 2009
    Assignee: Genentech, Inc.
    Inventors: Chuntharapai Anan, Jin K. Kim, Leonard G. Presta, Timothy Stewart
  • Injection vehicle for polymer-based formulations
    Patent number: 7582311
    Abstract: The invention provides injection vehicles suitable for administering particulate suspensions, such as polymer-based formulations, as well as associated pharmaceutical formulations, articles of manufacture, and kits. Other aspects of the invention included methods for producing and administering pharmaceutical formulations. The injection vehicles of the invention are superior to conventional injection vehicles in that they include a pseudoplastic composition that improves injectability, which facilitates delivery of the desired dose. The injection vehicles of the invention also allow the use of smaller-bore needles than are usually necessary to inject polymer-based formulations, reducing the pain associated with injection of such formulations.
    Type: Grant
    Filed: October 13, 2000
    Date of Patent: September 1, 2009
    Assignee: Genentech, Inc.
    Inventors: Jeffrey L. Cleland, Xanthe M. Lam, Franklin Okumu
  • PROCESS FOR CONCENTRATION OF ANTIBODIES AND THERAPEUTIC PRODUCTS THEREOF
    Publication number: 20090214522
    Abstract: The present disclosure provides a process for concentrating proteins including an ultrafiltering, a diafiltering, and a second ultrafiltering sequence, at elevated temperatures, such as above about 30° C. The disclosure also includes a process for preparing highly concentrated antibody compositions, and highly concentrated antibody products.
    Type: Application
    Filed: February 19, 2009
    Publication date: August 27, 2009
    Applicants: Genentech, Inc., Novartis AG
    Inventor: Charles M. WINTER
  • ANTI-EPHRINB2 ANTIBODIES AND METHODS USING SAME
    Publication number: 20090214564
    Abstract: The invention provides anti-EphrinB2 antibodies, and compositions comprising and methods of using these antibodies.
    Type: Application
    Filed: January 19, 2007
    Publication date: August 27, 2009
    Applicant: Genentech, Inc.
    Inventors: Yan Wu, Minhong Yan
  • Novel anti-IL13 antibodies and uses thereof
    Publication number: 20090214523
    Abstract: The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.
    Type: Application
    Filed: December 23, 2004
    Publication date: August 27, 2009
    Applicant: Genentech, Inc.
    Inventors: Sek Chung Fung, Matthew Moyle, Mason Lu, Changning Yan, Sanjaya Singh, Dan Huang
  • Assay methods for suppressor of fused modulation of hedgehog signaling
    Patent number: 7579161
    Abstract: The present invention is directed to novel polypeptides having homology to a polypeptide suppressor of the Drosophila melanogaster fused protein and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: April 1, 2005
    Date of Patent: August 25, 2009
    Assignee: Genentech, Inc.
    Inventors: Frederic J. de Sauvage, Maximilien Murone, Arnon Rosenthal, Donna M. Stone, Austin L. Gurney, William I. Wood
  • Purification of microbial cell fermentation homogenates
    Patent number: 7579448
    Abstract: A method for purifying a desired heterologous polypeptide from microbial fermentation broth or homogenate in which it is produced and solubilized is described. This method involves adding to the broth or homogenate an effective amount of a solution of 6,9-diamino-2-ethoxyacridine lactate (ethacridine lactate) to precipitate host cell impurities under conditions wherein the majority of polypeptide remains soluble, and separating the desired polypeptide from the broth or homogenate. The broth or homogenate containing the ethacridine lactate and polypeptide is also disclosed.
    Type: Grant
    Filed: December 12, 2006
    Date of Patent: August 25, 2009
    Assignee: Genentech, Inc.
    Inventors: Philip M. Lester, Josefine Persson
  • Method of producing antibodies with improved function
    Publication number: 20090208500
    Abstract: The invention provides methods for controlling fucosylation levels and improving ADCC activity in antibodies.
    Type: Application
    Filed: June 5, 2006
    Publication date: August 20, 2009
    Applicant: Genentech, Inc.
    Inventors: John C. Joly, Henry B. Lowman, Domingos Ng, Amy Y. Shen, Bradley R. Snedecor